Breaking News Instant updates and real-time market news.

AGN

Allergan

$166.31

1.25 (0.76%)

08:04
04/13/18
04/13
08:04
04/13/18
08:04

Allergan announces launch of TrueTear

Allergan announced the official launch of TrueTear, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients. The neurostimulation device will be officially launched during the 2018 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators annual meetings being held April 13-17 in Washington, DC.

  • 24

    Apr

  • 27

    Apr

  • 30

    Apr

  • 08

    May

AGN Allergan
$166.31

1.25 (0.76%)

03/14/18
RBCM
03/14/18
NO CHANGE
RBCM
Outperform
RBC says Allergan sent clear message that all strategic options being evaluated
RBC Capital analyst Randall Stanicky said that Allergan Chairman and CEO Brent Saunders and new CFO Matt Walsh sent a "clear" message while presenting earlier at an investor conference that all strategic options are being evaluated "with a sense of urgency." This message, which he said is the one he had hoped to hear, will keep the asset sale/break-up debate in the stock, said Stanicky. The analyst, who expects the Street's focus on asset sales to pick up following this, keeps an Outperform rating on Allergan shares.
03/15/18
JPMS
03/15/18
NO CHANGE
Target $265
JPMS
Overweight
Allergan CEO comments on evaluating options a 'clear positive,' says JPMorgan
JPMorgan analyst Chris Schott views Allergan CEO Brent Saunders' comments yesterday on evaluating all options to create value as a "clear positive." The company is focusing on core business execution with a set of near-term pipeline opportunities while also examining other potential value-unlocking options for the business, Schott tells investors in a research note. The analyst says he has long argued that Allergan's core business is "significantly undervalued" and that any shift toward greater Botox/aesthetics exposure would result in a company that trades at a "distinctly higher multiple" than the current business. As such, he believes selling or spinning off assets could unlock value. Schott keeps an Overweight rating on Allergan with a $265 price target.
03/26/18
WBLR
03/26/18
NO CHANGE
WBLR
Outperform
William Blair sees Biohaven safety as 'strong differentiator' versus Allergan
William Blair analyst Tim Lugo believes Biohaven Pharmaceutical's (BHVN) Phase III data this morning confirmed rimegepant's efficacy and "clean" safety profile. The analyst keeps an Outperform rating on the shares, which are trading down 29%, or $7.12, to $17.64. Lugo understands the focus on comparing today's results with the recent ubrogepant Phase III data from Allergan (AGN), but he notes that comparisons are complicated as Biohaven did not allow rescue medications or re-dosing. While the efficacy in Study 302 looked in line with Allergan's ubrogepant Phase III study, Study 301 looked to be affected by a higher placebo rate of a few percentage points, which negatively affected the difference versus placebo, Lugo tells investors in a research note. He believes safety for rimegepant is "impressive" and likely a " William Blair sees Biohaven safety as 'strong differentiator' versus AllerganWhile a drop-off in efficacy between Phase II and Phase III results is common, it may have been exacerbated as management noted the rimegepant formulation in the Phase III took 30 minutes longer to reach serum maximal concentration than the formulation used in Phase II, Lugo points out. Further, he thinks the profile of rimegepant could be boosted by the company's Phase III trial of a rapidly dissolving sublingual rimegepant formulation using Catalent's (CTLT) Zydis technology, which the analyst says should lead to a faster bioavailability.
04/12/18
DBAB
04/12/18
NO CHANGE
Target $212
DBAB
Buy
Deutsche Bank likes current setup for shares of Allergan
Allergan shares at current levels likely reflect concerns about the growth and durability of core franchises, low expectations for current pipeline assets, and skepticism about the company's ability to bolster the pipeline, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. His $212 price target includes value for only four late-stage pipeline assets, each with validating events in 2018. Removing these assets would reduce his target to $183, all else equal. Not all of the programs are likely to fail, Gilbert argues. As such, he likes the setup for the stock from here in the event of positive pipeline news and strong operational performance. He keeps a Buy rating on Allergan.

TODAY'S FREE FLY STORIES

BAC

Bank of America

$28.42

0.07 (0.25%)

, GE

General Electric

$12.29

-0.43 (-3.38%)

08:55
10/15/18
10/15
08:55
10/15/18
08:55
Options
Notable open interest changes for October 15th »

Friday's total…

BAC

Bank of America

$28.42

0.07 (0.25%)

GE

General Electric

$12.29

-0.43 (-3.38%)

AAPL

Apple

$222.10

7.61 (3.55%)

AMD

AMD

$26.37

1.07 (4.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

  • 24

    Oct

  • 06

    Dec

AAPL

Apple

$222.10

7.61 (3.55%)

08:55
10/15/18
10/15
08:55
10/15/18
08:55
Recommendations
Apple analyst commentary  »

China consumer slowdown…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$50.52

0.72 (1.45%)

08:55
10/15/18
10/15
08:55
10/15/18
08:55
Conference/Events
TD Ameritrade to hold a daily program »

TD Ameritrade Network, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HRS

Harris

$154.88

0.61 (0.40%)

, LLL

L3 Technologies

$195.99

0.74 (0.38%)

08:53
10/15/18
10/15
08:53
10/15/18
08:53
Recommendations
Harris, L3 Technologies analyst commentary  »

Harris, L3 should trade…

HRS

Harris

$154.88

0.61 (0.40%)

LLL

L3 Technologies

$195.99

0.74 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

KLAC

KLA-Tencor

$93.18

1.37 (1.49%)

08:53
10/15/18
10/15
08:53
10/15/18
08:53
Downgrade
KLA-Tencor rating change  »

KLA-Tencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:50
10/15/18
10/15
08:50
10/15/18
08:50
General news
Treasury Action: yields retreated on the damp retail sales print »

Treasury Action: yields…

SCHW

Charles Schwab

$49.02

0.89 (1.85%)

08:49
10/15/18
10/15
08:49
10/15/18
08:49
Earnings
Charles Schwab reports Q3 EPS 65c, consensus 65c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

WNC

Wabash

$13.54

-3.24 (-19.31%)

08:48
10/15/18
10/15
08:48
10/15/18
08:48
Recommendations
Wabash analyst commentary  »

Wabash price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

AQ

Aquantia

$11.45

0.13 (1.15%)

08:47
10/15/18
10/15
08:47
10/15/18
08:47
Initiation
Aquantia initiated  »

Aquantia initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

TDOC

Teladoc

$65.99

3.57 (5.72%)

08:46
10/15/18
10/15
08:46
10/15/18
08:46
Recommendations
Teladoc analyst commentary  »

Teladoc price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

ACRX

AcelRx

$3.95

(0.00%)

08:45
10/15/18
10/15
08:45
10/15/18
08:45
Recommendations
AcelRx analyst commentary  »

AcelRx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

CGC

Canopy Growth

$49.79

2.64 (5.60%)

, CWH

Camping World

$21.37

0.42 (2.00%)

08:45
10/15/18
10/15
08:45
10/15/18
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

CGC

Canopy Growth

$49.79

2.64 (5.60%)

CWH

Camping World

$21.37

0.42 (2.00%)

BLUE

Bluebird Bio

$125.92

-0.81 (-0.64%)

BGS

B&G Foods

$25.83

-0.16 (-0.62%)

CPB

Campbell Soup

$37.10

-0.05 (-0.13%)

IYT

iShares Transportation Average

$188.69

1.55 (0.83%)

NTR

Nutrien

$54.11

0.05 (0.09%)

SHPG

Shire

$170.37

2.14 (1.27%)

GERN

Geron

$1.69

0.02 (1.20%)

CX

Cemex

$6.23

0.145 (2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 28

    Oct

  • 06

    Nov

  • 13

    Nov

  • 01

    Dec

  • 21

    Dec

08:45
10/15/18
10/15
08:45
10/15/18
08:45
General news
FX Action: The dollar »

FX Action: The dollar…

08:45
10/15/18
10/15
08:45
10/15/18
08:45
General news
U.S. October Empire State index rebounded 2.1 ticks to 21.1 »

U.S. October Empire State…

BYD

Boyd Gaming

$31.86

0.13 (0.41%)

, GLPI

Gaming and Leisure Properties

$34.09

0.01 (0.03%)

08:43
10/15/18
10/15
08:43
10/15/18
08:43
Hot Stocks
Boyd Gaming completes acquisition of four Pinnacle Entertainment assets »

Boyd Gaming has completed…

BYD

Boyd Gaming

$31.86

0.13 (0.41%)

GLPI

Gaming and Leisure Properties

$34.09

0.01 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

ROK

Rockwell Automation

$172.89

2.3 (1.35%)

08:43
10/15/18
10/15
08:43
10/15/18
08:43
Downgrade
Rockwell Automation rating change  »

Rockwell Automation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$5.41

0.345 (6.82%)

08:43
10/15/18
10/15
08:43
10/15/18
08:43
Recommendations
Vipshop analyst commentary  »

Vipshop price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSI

FTS International

$12.21

0.3 (2.52%)

08:41
10/15/18
10/15
08:41
10/15/18
08:41
Upgrade
FTS International rating change  »

FTS International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

SPY

SPDR S&P 500 ETF Trust

$275.95

3.51 (1.29%)

, SPX

S&P 500

$0.00

(0.00%)

08:41
10/15/18
10/15
08:41
10/15/18
08:41
General news
Trump says Saudi Arabia's King denies knowledge of what happened to journalist »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$275.95

3.51 (1.29%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSC

Harsco

$24.87

-0.24 (-0.96%)

08:40
10/15/18
10/15
08:40
10/15/18
08:40
Hot Stocks
Harsco Rail awarded multiyear MTA contract valued at approx. $40M »

Harsco Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

08:40
10/15/18
10/15
08:40
10/15/18
08:40
General news
U.S. retail sales rose 0.1% in September, and fell 0.1% excluding autos »

U.S. retail sales rose…

KRYS

Krystal Biotech

$15.49

0.58 (3.89%)

08:40
10/15/18
10/15
08:40
10/15/18
08:40
Conference/Events
Krystal Biotech to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

DLGNF

Dialog Semiconductor

$0.00

(0.00%)

08:39
10/15/18
10/15
08:39
10/15/18
08:39
Upgrade
Dialog Semiconductor rating change  »

Dialog Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPI

Gaming and Leisure Properties

$34.09

0.01 (0.03%)

, PENN

Penn National

$29.91

1.33 (4.65%)

08:39
10/15/18
10/15
08:39
10/15/18
08:39
Hot Stocks
Gaming and Leisure enters into master lease with Boyd to include 3 properties »

Gaming and Leisure…

GLPI

Gaming and Leisure Properties

$34.09

0.01 (0.03%)

PENN

Penn National

$29.91

1.33 (4.65%)

PNK

Pinnacle Entertainment

$32.57

0.57 (1.78%)

BYD

Boyd Gaming

$31.86

0.13 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

TNDM

TNDM

08:39
10/15/18
10/15
08:39
10/15/18
08:39
Recommendations
TNDM analyst commentary  »

Tandem Diabetes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.